Y Intercept Hong Kong Ltd Trims Stake in Varex Imaging $VREX

Y Intercept Hong Kong Ltd cut its position in shares of Varex Imaging (NASDAQ:VREX) by 92.6% in the third quarter, HoldingsChannel reports. The firm owned 25,303 shares of the company’s stock after selling 318,294 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Varex Imaging were worth $314,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in VREX. State of Alaska Department of Revenue bought a new stake in shares of Varex Imaging in the third quarter valued at about $27,000. BNP Paribas Financial Markets raised its holdings in shares of Varex Imaging by 18.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,045 shares of the company’s stock valued at $113,000 after purchasing an additional 2,036 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Varex Imaging by 25.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 13,104 shares of the company’s stock worth $115,000 after purchasing an additional 2,659 shares during the period. Cerity Partners LLC bought a new position in shares of Varex Imaging during the second quarter valued at approximately $123,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Varex Imaging by 10.4% during the second quarter. The Manufacturers Life Insurance Company now owns 15,302 shares of the company’s stock valued at $133,000 after buying an additional 1,442 shares during the period.

Analyst Ratings Changes

A number of analysts have weighed in on VREX shares. Wall Street Zen upgraded Varex Imaging from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 22nd. Oppenheimer lowered their price target on shares of Varex Imaging from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Varex Imaging in a research note on Monday, December 29th. Jefferies Financial Group restated a “hold” rating and issued a $14.50 target price on shares of Varex Imaging in a research note on Monday. Finally, B. Riley reissued a “buy” rating and issued a $16.00 price objective on shares of Varex Imaging in a research report on Wednesday, November 19th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $16.17.

Varex Imaging Price Performance

Shares of VREX opened at $13.78 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.43 and a quick ratio of 1.83. The company’s fifty day moving average price is $12.68 and its 200-day moving average price is $11.55. Varex Imaging has a 1-year low of $6.76 and a 1-year high of $15.46. The firm has a market capitalization of $577.66 million, a PE ratio of -8.11 and a beta of 0.90.

Varex Imaging (NASDAQ:VREX) last issued its quarterly earnings results on Tuesday, November 18th. The company reported $0.37 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.19. The company had revenue of $228.90 million during the quarter, compared to analysts’ expectations of $219.26 million. Varex Imaging had a positive return on equity of 7.19% and a negative net margin of 8.32%.Varex Imaging has set its Q1 2026 guidance at 0.050-0.250 EPS. On average, equities research analysts predict that Varex Imaging will post 0.53 EPS for the current year.

Varex Imaging Profile

Varex Imaging Corporation is a global provider of X-ray imaging components and solutions for the medical, security and industrial markets. The company designs, develops and manufactures a broad range of products that convert X-ray energy into high-resolution digital images. Its portfolio includes X-ray tubes, flat panel detectors, digital sensors, specialty radiographic tubes and related software, all engineered to meet the demanding requirements of original equipment manufacturers (OEMs) in diagnostic imaging, computed tomography (CT), fluoroscopy, mammography, dental radiography and non-destructive testing applications.

The company’s medical imaging offerings support a wide spectrum of clinical modalities, from portable radiography systems to advanced CT scanners, enhancing image quality and dose efficiency for healthcare providers.